Quantitative Concept
AstraZeneca and Daiichi Sankyo’s Enhertu Denied NICE Recommendation for NHS Use, Prompting Calls for Review Process Reform
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, NHS, breast cancer treatment, cost-effectiveness, pricing dispute, review process reform
Fierce Biotech Layoff Tracker 2024: GlycoMimetics Cuts 80% of Company; Anokion Undergoes Cuts
Biotech Layoffs, GlycoMimetics, Anokion, Pharmaceutical Industry, Job Cuts, Cost Reduction
President Biden Highlights Achievements in Lowering Prescription Drug Costs as He Steps Down from Re-election Campaign
President Biden, drug pricing, re-election campaign, Medicare, Inflation Reduction Act, prescription drug costs, health care costs, pharmaceutical industry
Autobahn Therapeutics Advances to Phase II for Mood Disorders with $100M Financing
Autobahn Therapeutics, Phase II, Mood Disorders, Financing, Pharmaceutical Industry
Sanofi’s Dupixent Sales Surpass €3 Billion for the First Time
Sanofi, Dupixent, quarterly sales, record high, asthma medicine, earnings forecast
PBM Executives Avoid Tough Questions in House Committee Hearing
PBM executives, House committee hearing, pharmacy benefit managers, CVS Caremark, Express Scripts, Optum Rx
Canaan Partners Raises Additional $100M for Biotech Investments, Adds Pfizer Vet Uwe Schoenbeck
Canaan Partners, Biotech investments, Venture capital, Pfizer, Uwe Schoenbeck, Biopharma, Healthcare, Venture partner
Third Arc Bio Debuts with $165M Funding and Former J&J Executives at the Helm
Third Arc Bio, J&J, biotech, funding, executives, cancer, immune disease
PhRMA Intensifies Pricing Criticism, Targets Shared Ownership of Insurers and PBMs in New Ad
PhRMA, pricing attack, shared ownership, insurers, PBMs, new ad
Biopharma Layoff Tracker 2024: Thousands of Jobs Cut Across Industry Giants
Biopharma Layoffs, 2024, Industry Giants, Job Cuts, Restructuring, Cost Savings